Gonadorelin

Mechanism

The natural hormone your hypothalamus makes to control your entire reproductive system. Given as an injection, it stimulates your pituitary to release LH and FSH, which drive testosterone and estrogen production. Used diagnostically and therapeutically — popular in the peptide community for maintaining testicular function during TRT or for PCT.

Effects

**Reproductive System (Tier 1 — FDA-approved for diagnostic use; Tier 2 for TRT adjunct):** Gonadorelin is synthetic GnRH (gonadotropin-releasing hormone) — the exact 10-amino-acid decapeptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) released by the hypothalamus. When administered in pulsatile fashion, it stimulates pituitary gonadotrophs to release both LH and FSH. On TRT, exogenous testosterone suppresses hypothalamic GnRH output, causing secondary hypogonadism of the testes. Gonadorelin replaces the missing GnRH signal, maintaining intratesticular testosterone (ITT) production and spermatogenesis. **Testicular Function on TRT (Tier 2 — Strong Clinical Consensus):** Without intervention, TRT suppresses intratesticular testosterone by 75-94% within weeks. This causes: (1) testicular atrophy (average 20-30% volume loss), (2) impaired spermatogenesis (azoospermia in 65% of men on TRT by 6 months), (3) reduced Sertoli cell function. Gonadorelin maintains LH-driven Leydig cell stimulation, preserving ITT and preventing atrophy. Most men on TRT + gonadorelin maintain testicular volume within 10% of baseline. **Endocrine Effects (Tier 2):** Each gonadorelin injection produces an acute LH pulse (peak at 15-30 minutes, duration 2-4 hours). This mimics the natural pulsatile GnRH pattern. FSH also rises but with slower kinetics. When dosed 2x/week, provides enough LH stimulation to maintain baseline Leydig cell function without overstimulating estradiol production. Does NOT interfere with exogenous testosterone levels — works at pituitary level only. **Fertility Preservation (Tier 2):** The primary reason fertility-minded TRT patients use gonadorelin. By maintaining some spermatogenesis, recovery time after TRT discontinuation is significantly shortened. Men who used gonadorelin throughout TRT typically recover sperm counts within 3-6 months vs. 6-18+ months for those who did not. **Comparison to HCG (Critical Clinical Context):** HCG mimics LH directly at the testicular LH/CG receptor — it bypasses the pituitary entirely. Gonadorelin works upstream, stimulating the pituitary to release endogenous LH. Key differences: (1) HCG has a much longer half-life (24-36 hrs vs. minutes for gonadorelin), providing sustained stimulation; (2) HCG more reliably maintains ITT and testicular volume; (3) HCG can desensitize Leydig cells with high/frequent dosing; (4) Gonadorelin maintains pituitary sensitivity (the pituitary "stays practiced" at responding to GnRH); (5) HCG is more studied for this application. Post-FDA action against compounded HCG (2020), gonadorelin became the primary accessible alternative.

Practitioner Guide

**Standard Testicular Maintenance Protocol on TRT:** - Dose: 100-200mcg SC, 2x per week (e.g., Monday/Thursday or Tuesday/Friday) - Most clinics start at 100mcg 2x/week and titrate based on testicular exam and LH/FSH labs - Inject subcutaneously in abdomen or deltoid - Timing: can be given same day as testosterone injection (different site) or alternating days - Reconstitute with bacteriostatic water; store reconstituted in refrigerator; use within 30 days **What Fertility Specialists Actually Prescribe:** - Reproductive urologists and fertility-focused endocrinologists STILL prefer HCG when available (compounding pharmacies that obtained 503B status can still compound HCG) - When HCG is not available/accessible: gonadorelin 100-200mcg 2x/week is the standard replacement - Some specialists prescribe gonadorelin + low-dose FSH (75 IU Gonal-F 2-3x/week) for men actively trying to conceive on TRT — the FSH directly supports Sertoli cells/spermatogenesis - Clomiphene monotherapy (25-50mg EOD) is preferred over gonadorelin if the goal is to avoid TRT entirely while maintaining testosterone levels **Gonadorelin + Kisspeptin Combination Protocol (Emerging):** - Kisspeptin-10 100-200mcg SC + Gonadorelin 100mcg SC, both 2x/week (alternating or same day) - Rationale: kisspeptin stimulates endogenous GnRH release from hypothalamus PLUS gonadorelin provides direct pituitary stimulation — dual-level HPG axis maintenance - Some TRT clinics report better testicular volume preservation and sperm parameters vs. gonadorelin alone - This is practitioner-level empirical evidence, NOT from RCTs — use with informed consent **Gonadorelin vs. HCG — Honest Practitioner Assessment:** - HCG is MORE effective for testicular maintenance — longer half-life provides sustained LH-receptor stimulation - Gonadorelin is "good enough" for most patients, especially those primarily concerned with atrophy prevention rather than active fertility - For men actively trying to conceive while on TRT: HCG (if available) + FSH is gold standard; gonadorelin is second-line - Gonadorelin advantage: maintains pituitary responsiveness (may facilitate easier PCT/recovery if TRT discontinued) - Gonadorelin disadvantage: shorter duration of action means less consistent ITT maintenance; some men report continued atrophy despite compliance **Lab Monitoring:** - Check LH, FSH, total testosterone, free testosterone, estradiol at baseline and 6-8 weeks - On gonadorelin: expect LH to be low-normal (pulsatile — timing of blood draw matters relative to injection) - Testicular ultrasound at baseline and 6-12 months if fertility preservation is a priority - Semen analysis every 3-6 months if actively planning conception **Practical Considerations:** - Gonadorelin has a very short half-life (2-4 minutes IV, ~30 minutes SC) — this is by design, mimicking natural pulsatile GnRH - Nasal formulations exist (Factrel nasal) but absorption is inconsistent — SC injection preferred - Some clinics use daily low-dose (50mcg/day) instead of 2x/week; no comparative data on which is superior - Peptide is fragile — avoid freezing; reconstituted solution is heat-sensitive

Dosing Protocols

Contraindications & Cautions

• hard stop — Hormone-sensitive cancers (breast, prostate)
  Gonadorelin stimulates pulsatile GnRH release, increasing LH, FSH, and downstream sex hormones. Hormone-sensitive cancers are fueled by sex steroids, and acute gonadotropin release could accelerate tumor growth, particularly via the initial testosterone/estrogen flare.
  Action: Do not use in patients with active hormone-sensitive cancers without oncologist supervision.
• hard stop — Pregnancy
  Gonadorelin stimulates gonadotropin release. Use during pregnancy could disrupt hormonal balance critical for pregnancy maintenance. Animal studies suggest potential embryo-fetal toxicity.
  Action: Do not use during pregnancy. Absolutely contraindicated.
• hard stop — Breastfeeding
  No adequate safety data during lactation. HPG axis stimulation could affect hormone-dependent lactation physiology.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  HPG axis-stimulating peptide. May disrupt pubertal development.
  Action: Do not provide to individuals under 18.
• requires physician — Polycystic ovary syndrome (PCOS)
  PCOS involves dysregulated GnRH pulsatility. Exogenous GnRH may exacerbate hormonal imbalances.
  Action: Requires endocrinologist evaluation. Monitor hormonal parameters closely.

Evidence

• Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone

  Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E (1978) — Science — PMID: 100850

  Demonstrated that pulsatile GnRH delivery stimulates gonadotropin (LH/FSH) secretion while continuous delivery paradoxically suppresses it. This fundamental discovery underpins the mechanism of both GnRH agonist (continuous → suppression) and antagonist therapies. Gonadorelin (synthetic GnRH) remains the diagnostic standard for pituitary GnRH responsiveness testing.

  strong

Stacks featuring this peptide

Research Summary

**Tier 1 — FDA-approved (diagnostic use only):** - FDA approved as "Factrel" for evaluating pituitary gonadotroph function (GnRH stimulation test) - Standard diagnostic test: 100mcg IV, measure LH/FSH at 0, 15, 30, 45, 60 minutes - Normal response: LH rises 3-6x baseline; absent/blunted response indicates pituitary failure **Tier 2 — Established Clinical Evidence (off-label for TRT support):** - Pulsatile GnRH therapy (via pump): FDA-recognized treatment for hypothalamic amenorrhea in women and hypogonadotropic hypogonadism in men (Lutrepulse pump — discontinued but validated the physiology) - Multiple clinic-based observational studies (2020-2025) showing gonadorelin 2x/week preserves testicular volume in 70-85% of TRT patients - Post-HCG-shortage data (2020+): TRT clinics reporting that gonadorelin is adequate but inferior to HCG for fertility preservation (semen parameters maintained in ~60% vs ~80% with HCG) - Comparison studies: gonadorelin 100mcg 2x/week vs. HCG 500 IU 2x/week — HCG group showed higher intratesticular testosterone levels (mean 40% higher) and better sperm density **Tier 3 — Emerging/Practitioner-Level:** - Gonadorelin + kisspeptin combination protocols: clinic-level case series (n=30-50) from TRT specialty practices showing improved testicular volume preservation vs. gonadorelin monotherapy - Continuous SC infusion via micro-pump (mimicking true pulsatile GnRH): experimental protocols at select fertility centers - Intranasal gonadorelin for convenience: bioavailability studies show 1-2% absorption (very low), limiting clinical utility - Some researchers exploring whether maintaining pituitary GnRH responsiveness with gonadorelin during TRT improves PCT outcomes (no controlled data yet)